Vertex Pharmaceuticals Inc (VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Industry: Pharmaceutical Preparations (SIC 2834)

Market region: US

Address: 50 Northern Avenue, Boston, MA, 02210

Market capitalization

141.65 billion USD (141,654,241,205 USD)

Listing date

07/31/1991

Weighted shares outstanding

253,460,924

Share class shares outstanding

253,805,417

https://www.vrtx.com